Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain

Radiolabeled Affibody-based targeting agent (177)Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumin prevents glomerular...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmaceutics
Egile Nagusiak: Liu, Yongsheng, Vorobyeva, Anzhelika, Xu, Tianqi, Orlova, Anna, Loftenius, Annika, Bengtsson, Theresa, Jonasson, Per, Tolmachev, Vladimir, Frejd, Fredrik Y.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8226825/
https://ncbi.nlm.nih.gov/pubmed/34200197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13060839
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak